(Q40559728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study (English)

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

author name string

Paolo Tralongo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Roberto Bollina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Rosanna Aiello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Anna Di Mari

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Giovanni Moruzzi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gianni Beretta

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gaetano Mauceri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Gianfranco Conti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12729357

30 December 2023

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

3 November 2019

http://journals.sagepub.com/doi/pdf/10.1177/030089160308900106

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

26-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly

3 November 2019

cites work

3

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

Cancer statistics, 1997.

5

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

30 December 2023

8

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

30 December 2023

9

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Vinorelbine (Navelbine): a third-generation vinca alkaloid

30 December 2023

10

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

Vinorelbine: an overview

11

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

30 December 2023

12

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

30 December 2023

13

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

30 December 2023

14

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

30 December 2023

15

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

The McGill Pain Questionnaire: Major properties and scoring methods

30 December 2023

17

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Nonparametric Estimation from Incomplete Observations

30 December 2023

18

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Management of cancer of the prostate

30 December 2023

20

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

30 December 2023

21

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

30 December 2023

22

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

30 December 2023

23

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

30 December 2023

24

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

30 December 2023

25

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

30 December 2023

26

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

30 December 2023

27

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

30 December 2023

28

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

30 December 2023

29

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

30 December 2023

30

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

30 December 2023

31

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

30 December 2023

32

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer

30 December 2023

33

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study

30 December 2023

35

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer

30 December 2023

39

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

30 December 2023

40

1 reference

https://api.crossref.org/works/10.1177/030089160308900106

30 December 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12729357%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference